Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults [Phase 2]

View source ↗

Summary

Phase 2 trial comparing GSK 134612 with Menactra in healthy adolescents and adults to evaluate immunogenicity and safety; results were posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK 134612
• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2017-06-08